Alumis, a clinical-stage immunology biotech company, has priced its downsized initial public offering (IPO) at $16 per share, at the lower end of its projected range. This move highlights the cautious sentiment in the biotech market, reflecting broader industry trends and investor hesitancy.
Company Background
Founded in 2021 and based in South San Francisco, Alumis focuses on developing innovative treatments for immune-mediated diseases. The company leverages its expertise in precision data analytics and biological insights to accelerate the development and commercialization of transformative medicines. Alumis’ strategic focus is on targeting kinase inhibitors, particularly Tyrosine Kinase 2 (TYK2) inhibitors,
